The Mark Foundation for Cancer Research announced the recipients of its 2023 Endeavor Award program, providing a total of $12 million across seven institutions to support teams of scientists tackling a range of urgent challenges in the prevention, diagnosis, and treatment of cancer.
Data from the phase Ib/II OrigAMI-4 study found that first-line treatment with investigational subcutaneous amivantamab and hyaluronidase-lpuj in combination with a PD-1 inhibitor delivered clinically meaningful and durable antitumor activity in patients with head and neck squamous cell carcinoma that is recurrent or metastatic, PD-L1-positive, and HPV-unrelated.
